|
 12th Biosimilars Americas15th - 17th April 2013, The Seaport Hotel, Boston, USA
The global pharmaceutical biological drug market is one of the fastest growing sectors generating revenue of $114.8bn in 2010, which corresponds to over 15% of the total pharmaceutical market. There is a large and potentially lucrative demand for lower cost biological drugs worldwide. Following the huge success of our events in Boston and London, the 12th Annual Biosimilars conference will face important questions associated with cost-effective methods of developing biosimilars, key regulatory issues, safety assessments both clinical & non-clinical methods and the future of biosimilars. |
 3rd Cell-Based Assays UK6th - 7th February 2013, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Cell-Based Assays (CBA) investigate the in vivo properties and effects of a drug molecule due to the cells ability to replicate normal processes that would occur in the body. With the cost of developing a new drug for market launch estimated to be over $1bn, this method of drug testing has the potential to save pharmaceutical companies millions through "fail early" techniques. These allow companies to detect any adverse effects that may occur in human cells that may not have been detected in animal cells. This can limit the chances of a medication failing in late stage clinical testing. |
 5th Pre-Filled Syringes20th - 21st November 2012, Holiday Inn Kings Cross/Bloomsbury, 1 Kingscross Road, WC1X 9HX, UK
Pre-filled syringes constitutes one of the fastest growing markets in the drug delivery and packaging sectors with total revenues in this market expected to reach $5.5bn in 2025. It continues to offer one of the highest growth potentials in the pharmaceutical industry with 20% CAGR over the past 5 years. |
 Single-Use Bioreactors1st - 2nd November 2012, Thistle Barbican, Clerkenwell, EC1V 8DS, UK
In the bioreactors market, disposables are one of the fastest growing sectors with the potential for many new breakthroughs and applications in the coming years. They are an attractive alternative to the traditional large inflexible stainless steel bioreactors which require substantial capital expenditure. The industry as a whole is experiencing an increased demand for biologics which requires the use of bioreactors to cultivate specific cell lines. The number of clinical monoclonal antibodies (mAbs) in development is increasing and pharmaceutical companies are looking at developing a diverse pipeline of mAbs to fill several smaller niches and meet the demand for personalised medicine rather than large scale production of blockbusters. This has resulted in the industry demanding smaller batch sizes, quicker turnover rates and cheaper production costs as budgets are restrained. |
 11th Annual Biosimilars UK29th - 31st October 2012, Holiday Inn Kings Cross/Bloomsbury, London, WC1X 9HX, UK
With a patent cliff looming in the future, the market for biological therapeutics is looking to undergo radical changes. Both producers of branded drugs and upstarts looking to meet the demand for cost-effective healthcare, will be looking to find the best strategies and solutions to compete in this dynamic environment. It is more critical than ever to make sure your company's plan to tackle the issues of litigation, pricing and reimbursement, regulatory approval and risk management meet the benchmarks set by industry leaders. |
 6th Lyophilisation4th - 6th September 2012, Thistle City Barbican, London, EC1V 8DS, UK
Lyophilisation continues to maintain a dominant position among the preservation techniques for various biopharmaceuticals. Currently over 50% of medicinal products must be freeze-dried due to their instability in the liquid state. Recent estimates of the market value of the sector suggest it is worth over $1.99bn, and constant introduction of new biologic drugs will drive further demand for lyophilisation services and technologies. |
 Cell Based Assays Americas19th - 20th July 2012, The Seaport Hotel, Boston, USA
Drugs recalls due to toxicity not only have a huge effect on the cost of developing new therapeutics but it also leads to many years of wasted research. That is why it is vital to get things right from the outset with more precise testing of new leads using more accurate in-vitro models. High Throughput Screening using biochemical assays has been a mainstay of the pharmaceutical industry in the past, but with the cost of developing a single lead reaching exorbitant amounts, it is now necessary to look at more cost-efficient methods that more accurately represent the in-vivo environment. |
 7th Annual Pharmaceutical Anti-Counterfeiting26th - 27th June 2012, Thistle City Barbican, London, EC1V 8DS, UK
Counterfeit medications are becoming a huge problem for many aspects of the pharmaceutical community from big pharma companies, through to wholesalers and down to end user level where patients are affected. The FDA estimates that 10% of the global market is counterfeit however there is no accurate way to measure this. |
 2nd Annual Biobanking Americas 201213th - 14th June 2012, The Seaport Hotel, Boston, USA
Biobanking offers immense opportunities for the entire pharmaceutical market, potentially opening ways to new drug discovery, and personalized medicine. It is not surprising the sector is expanding at such a rate that its total sales are predicted to triple in the next decade and reach $37.62bn by 2022, growing at CAGR of 15.7%.
Visiongain's Biobanking Americas 2012 Conference will highlight the latest technological advances in the biobanking sector, most recent progress in the implementation of standard operating procedures, and current social perspective on the biobanking industry. |
 8th Monoclonal Antibodies23rd - 24th May 2012, Thistle City Barbican, London, UK
Generating annual sales of almost $50bn per year monoclonal antibodies continue to play a vital role in the biopharmaceutical development and represent 42% of the total market. Anticipated steady growth at an annual rate of 6.9% suggests the revenues will reach over $63bn/year by 2015. Primarily driven by the oncology and autoimmune disease treatments, the industry's window will be significantly widened by the introduction of mAbs with novel indications and increasing penetration of the emerging economies. |
|